{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:26:22Z","timestamp":1793499982643,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX003168"],"award-info":[{"award-number":["BX003168"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS080881"],"award-info":[{"award-number":["NS080881"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS123211"],"award-info":[{"award-number":["NS123211"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS043277"],"award-info":[{"award-number":["NS043277"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke"},{"DOI":"10.13039\/100008539","name":"CurePSP","doi-asserted-by":"publisher","award":["468-08"],"award-info":[{"award-number":["468-08"]}],"id":[{"id":"10.13039\/100008539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008539","name":"CurePSP","doi-asserted-by":"publisher","award":["655-2018-06"],"award-info":[{"award-number":["655-2018-06"]}],"id":[{"id":"10.13039\/100008539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["AG066468"],"award-info":[{"award-number":["AG066468"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Progressive supranuclear palsy (PSP) is an incurable neurodegenerative disease characterized by 4-repeat (0N\/4R)-Tau protein accumulation in CNS neurons. We generated transgenic zebrafish expressing human 0N\/4R-Tau to investigate PSP pathophysiology. Tau zebrafish replicated multiple features of PSP, including: decreased survival; hypokinesia; impaired optokinetic responses; neurodegeneration; neuroinflammation; synapse loss; and Tau hyperphosphorylation, misfolding, mislocalization, insolubility, truncation, and oligomerization. Using automated assays, we screened 147 small molecules for activity in rescuing neurological deficits in Tau zebrafish. (+)JQ1, a bromodomain inhibitor, improved hypokinesia, survival, microgliosis, and brain synapse elimination. A heterozygous <jats:italic>brd4<\/jats:italic><jats:sup>+\/\u2212<\/jats:sup> mutant reducing expression of the bromodomain protein Brd4 similarly rescued these phenotypes. Microglial phagocytosis of synaptic material was decreased by (+)JQ1 in both Tau zebrafish and rat primary cortical cultures. Microglia in human PSP brains expressed Brd4. Our findings implicate Brd4 as a regulator of microglial synaptic elimination in tauopathy and provide an unbiased approach for identifying mechanisms and therapeutic targets in PSP.<\/jats:p>","DOI":"10.1038\/s41467-024-52173-0","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T22:55:51Z","timestamp":1726786551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A human Tau expressing zebrafish model of progressive supranuclear palsy identifies Brd4 as a regulator of microglial synaptic elimination"],"prefix":"10.1038","volume":"15","author":[{"given":"Qing","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enhua","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denglei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binxuan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth D.","family":"Scheetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8078-7366","authenticated-orcid":false,"given":"Karen A.","family":"Hartnett-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir A.","family":"Ilin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9610-4194","authenticated-orcid":false,"given":"Elias","family":"Aizenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kofler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8072-4636","authenticated-orcid":false,"given":"Edward A.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"52173_CR1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/archneur.1964.00460160003001","volume":"10","author":"JC Steele","year":"1964","unstructured":"Steele, J. C., Richardson, J. C. & Olszewski, J. Progressive Supranuclear Palsy. A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum with Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia. Arch. Neurol. 10, 333\u2013359 (1964).","journal-title":"Arch. Neurol."},{"key":"52173_CR2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41582-021-00541-5","volume":"17","author":"M Stamelou","year":"2021","unstructured":"Stamelou, M. et al. Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. Nat. Rev. Neurol. 17, 601\u2013620 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"52173_CR3","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/brain\/awm032","volume":"130","author":"LI Golbe","year":"2007","unstructured":"Golbe, L. I. & Ohman-Strickland, P. A. A clinical rating scale for progressive supranuclear palsy. Brain 130, 1552\u20131565 (2007).","journal-title":"Brain"},{"key":"52173_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/jnnp.2009.195719","volume":"81","author":"WZ Chiu","year":"2010","unstructured":"Chiu, W. Z. et al. Survival in progressive supranuclear palsy and frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 81, 441\u2013445 (2010).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"52173_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1750-3639.2007.00054.x","volume":"17","author":"DW Dickson","year":"2007","unstructured":"Dickson, D. W., Rademakers, R. & Hutton, M. L. Progressive supranuclear palsy: pathology and genetics. Brain Pathol. 17, 74\u201382 (2007).","journal-title":"Brain Pathol."},{"key":"52173_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s004010000283","volume":"101","author":"T Arai","year":"2001","unstructured":"Arai, T. et al. Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick\u2019s disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol. 101, 167\u2013173 (2001).","journal-title":"Acta Neuropathol."},{"key":"52173_CR7","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1046\/j.1471-4159.1999.0721243.x","volume":"72","author":"N Sergeant","year":"1999","unstructured":"Sergeant, N., Wattez, A. & Delacourte, A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively \u201cexon 10\u201d isoforms. J. Neurochem. 72, 1243\u20131249 (1999).","journal-title":"J. Neurochem."},{"key":"52173_CR8","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/31508","volume":"393","author":"M Hutton","year":"1998","unstructured":"Hutton, M. et al. Association of missense and 5\u2019-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702\u2013705 (1998).","journal-title":"Nature"},{"key":"52173_CR9","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1093\/hmg\/ddl429","volume":"15","author":"TM Caffrey","year":"2006","unstructured":"Caffrey, T. M., Joachim, C., Paracchini, S., Esiri, M. M. & Wade-Martins, R. Haplotype-specific expression of exon 10 at the human MAPT locus. Hum. Mol. Genet. 15, 3529\u20133537 (2006).","journal-title":"Hum. Mol. Genet."},{"key":"52173_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/hmg\/8.4.711","volume":"8","author":"M Baker","year":"1999","unstructured":"Baker, M. et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 8, 711\u2013715 (1999).","journal-title":"Hum. Mol. Genet."},{"key":"52173_CR11","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/mds.27702","volume":"34","author":"Z Chen","year":"2019","unstructured":"Chen, Z. et al. Genome-wide survey of copy number variants finds MAPT duplications in progressive supranuclear palsy. Mov. Disord. 34, 1049\u20131059 (2019).","journal-title":"Mov. Disord."},{"key":"52173_CR12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/ng.859","volume":"43","author":"GU Hoglinger","year":"2011","unstructured":"Hoglinger, G. U. et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat. Genet 43, 699\u2013705 (2011).","journal-title":"Nat. Genet"},{"key":"52173_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13024-018-0267-3","volume":"13","author":"MY Sanchez-Contreras","year":"2018","unstructured":"Sanchez-Contreras, M. Y. et al. Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Mol. Neurodegener. 13, 37 (2018).","journal-title":"Mol. Neurodegener."},{"key":"52173_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/mds.25824","volume":"29","author":"E Tolosa","year":"2014","unstructured":"Tolosa, E. et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov. Disord. 29, 470\u2013478 (2014).","journal-title":"Mov. Disord."},{"key":"52173_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","volume":"20","author":"GU H\u00f6glinger","year":"2021","unstructured":"H\u00f6glinger, G. U. et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol. 20, 182\u2013192 (2021).","journal-title":"Lancet Neurol."},{"key":"52173_CR16","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","volume":"27","author":"T Dam","year":"2021","unstructured":"Dam, T. et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat. Med. 27, 1451\u20131457 (2021).","journal-title":"Nat. Med."},{"key":"52173_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrd3480","volume":"10","author":"DC Swinney","year":"2011","unstructured":"Swinney, D. C. & Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discov. 10, 507\u2013519 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"52173_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/oons\/kvac018","volume":"2","author":"HA Burgess","year":"2023","unstructured":"Burgess, H. A. & Burton, E. A. A Critical Review of Zebrafish Neurological Disease Models\u22121. The Premise: Neuroanatomical, Cellular and Genetic Homology and Experimental Tractability. Oxf. Open Neurosci. 2, 1\u201316 (2023).","journal-title":"Oxf. Open Neurosci."},{"key":"52173_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/oons\/kvac019","volume":"2","author":"EA Burton","year":"2023","unstructured":"Burton, E. A. & Burgess, H. A. A Critical Review of Zebrafish Neurological Disease Models\u22122. Application: Functional and Neuroanatomical Phenotyping Strategies and Chemical Screens. Oxf. Open Neurosci. 2, 1\u201315 (2023).","journal-title":"Oxf. Open Neurosci."},{"key":"52173_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.bbadis.2010.09.004","volume":"1812","author":"Q Bai","year":"2011","unstructured":"Bai, Q. & Burton, E. A. Zebrafish models of Tauopathy. Biochim Biophys. Acta 1812, 353\u2013363 (2011).","journal-title":"Biochim Biophys. Acta"},{"key":"52173_CR21","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1172\/JCI37537","volume":"119","author":"D Paquet","year":"2009","unstructured":"Paquet, D. et al. A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J. Clin. Invest 119, 1382\u20131395 (2009).","journal-title":"J. Clin. Invest"},{"key":"52173_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13311-5","volume":"7","author":"MI Cosacak","year":"2017","unstructured":"Cosacak, M. I. et al. Human TAUP301L overexpression results in TAU hyperphosphorylation without neurofibrillary tangles in adult zebrafish brain. Sci. Rep. 7, 12959 (2017).","journal-title":"Sci. Rep."},{"key":"52173_CR23","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1093\/nar\/gkm608","volume":"35","author":"Q Bai","year":"2007","unstructured":"Bai, Q., Garver, J. A., Hukriede, N. A. & Burton, E. A. Generation of a transgenic zebrafish model of Tauopathy using a novel promoter element derived from the zebrafish eno2 gene. Nucleic Acids Res. 35, 6501\u20136516 (2007).","journal-title":"Nucleic Acids Res."},{"key":"52173_CR24","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/jnr.10451","volume":"70","author":"HG Tomasiewicz","year":"2002","unstructured":"Tomasiewicz, H. G., Flaherty, D. B., Soria, J. P. & Wood, J. G. Transgenic zebrafish model of neurodegeneration. J. Neurosci. Res. 70, 734\u2013745 (2002).","journal-title":"J. Neurosci. Res."},{"key":"52173_CR25","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/brain\/awx005","volume":"140","author":"A Lopez","year":"2017","unstructured":"Lopez, A. et al. A152T tau allele causes neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction. Brain 140, 1128\u20131146 (2017).","journal-title":"Brain"},{"key":"52173_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/dvg.20338","volume":"45","author":"E Provost","year":"2007","unstructured":"Provost, E., Rhee, J. & Leach, S. D. Viral 2A peptides allow expression of multiple proteins from a single ORF in transgenic zebrafish embryos. Genesis 45, 625\u2013629 (2007).","journal-title":"Genesis"},{"key":"52173_CR27","doi-asserted-by":"publisher","first-page":"e1002638","DOI":"10.1371\/journal.pgen.1002638","volume":"8","author":"TJ Stevenson","year":"2012","unstructured":"Stevenson, T. J. et al. Hypoxia Disruption of Vertebrate CNS Pathfinding through EphrinB2 Is Rescued by Magnesium. PLOS Genet. 8, e1002638 (2012).","journal-title":"PLOS Genet."},{"key":"52173_CR28","doi-asserted-by":"crossref","unstructured":"Chen, M., Martins, R. N., Lardelli, M. Complex Splicing and Neural Expression of Duplicated Tau Genes in Zebrafish Embryos. J. Alzheimers Dis., 18, 305\u2013317 (2009).","DOI":"10.3233\/JAD-2009-1145"},{"key":"52173_CR29","doi-asserted-by":"publisher","first-page":"101695","DOI":"10.1016\/j.redox.2020.101695","volume":"37","author":"VS Van Laar","year":"2020","unstructured":"Van Laar, V. S. et al. \u03b1-Synuclein amplifies cytoplasmic peroxide flux and oxidative stress provoked by mitochondrial inhibitors in CNS dopaminergic neurons in vivo. Redox Biol. 37, 101695 (2020).","journal-title":"Redox Biol."},{"key":"52173_CR30","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/jnr.490390607","volume":"39","author":"L Otvos Jr.","year":"1994","unstructured":"Otvos, L. Jr. et al. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J. Neurosci. Res. 39, 669\u2013673 (1994).","journal-title":"J. Neurosci. Res."},{"key":"52173_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E","volume":"48","author":"GA Jicha","year":"1997","unstructured":"Jicha, G. A., Bowser, R., Kazam, I. G. & Davies, P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J. Neurosci. Res. 48, 128\u2013132 (1997).","journal-title":"J. Neurosci. Res."},{"key":"52173_CR32","doi-asserted-by":"publisher","first-page":"10032","DOI":"10.1073\/pnas.1630428100","volume":"100","author":"TC Gamblin","year":"2003","unstructured":"Gamblin, T. C. et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer\u2019s disease. Proc. Natl Acad. Sci. USA 100, 10032\u201310037 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"52173_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1126\/science.1062382","volume":"293","author":"CW Wittmann","year":"2001","unstructured":"Wittmann, C. W. et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293, 711\u2013714 (2001).","journal-title":"Science"},{"key":"52173_CR34","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/nature08890","volume":"464","author":"A de Calignon","year":"2010","unstructured":"de Calignon, A. et al. Caspase activation precedes and leads to tangles. Nature 464, 1201\u20131204 (2010).","journal-title":"Nature"},{"key":"52173_CR35","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/nprot.2014.094","volume":"9","author":"Y Zhou","year":"2014","unstructured":"Zhou, Y., Cattley, R. T., Cario, C. L., Bai, Q. & Burton, E. A. Quantification of larval zebrafish motor function in multiwell plates using open-source MATLAB applications. Nat. Protoc. 9, 1533\u20131548 (2014).","journal-title":"Nat. Protoc."},{"key":"52173_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.nbd.2011.05.016","volume":"44","author":"TC Farrell","year":"2011","unstructured":"Farrell, T. C. et al. Evaluation of spontaneous propulsive movement as a screening tool to detect rescue of Parkinsonism phenotypes in zebrafish models. Neurobiol. Dis. 44, 9\u201318 (2011).","journal-title":"Neurobiol. Dis."},{"key":"52173_CR37","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1113\/jphysiol.2011.207308","volume":"589","author":"CL Cario","year":"2011","unstructured":"Cario, C. L., Farrell, T. C., Milanese, C. & Burton, E. A. Automated measurement of zebrafish larval movement. J. Physiol. 589, 3703\u20133708 (2011).","journal-title":"J. Physiol."},{"key":"52173_CR38","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1002\/jnr.25118","volume":"100","author":"D Hossainian","year":"2022","unstructured":"Hossainian, D. et al. Quantification of functional recovery in a larval zebrafish model of spinal cord injury. J. Neurosci. Res 100, 2044\u20132054 (2022).","journal-title":"J. Neurosci. Res"},{"key":"52173_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.neulet.2018.01.055","volume":"671","author":"E Shao","year":"2018","unstructured":"Shao, E., Scheetz, S. D., Xie, W. & Burton, E. A. Modulation of the zebrafish optokinetic reflex by pharmacologic agents targeting GABAA receptors. Neurosci. Lett. 671, 33\u201337 (2018).","journal-title":"Neurosci. Lett."},{"key":"52173_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jneumeth.2017.10.012","volume":"293","author":"SD Scheetz","year":"2018","unstructured":"Scheetz, S. D. et al. An open-source method to analyze optokinetic reflex responses in larval zebrafish. J. Neurosci. Methods 293, 329\u2013337 (2018).","journal-title":"J. Neurosci. Methods"},{"key":"52173_CR41","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1136\/jnnp.2003.027367","volume":"75","author":"S Garbutt","year":"2004","unstructured":"Garbutt, S. et al. Abnormalities of optokinetic nystagmus in progressive supranuclear palsy. J. Neurol. Neurosurg. Psychiatry 75, 1386\u20131394 (2004).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"52173_CR42","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1021\/acsmedchemlett.9b00063","volume":"10","author":"K Long","year":"2019","unstructured":"Long, K., Kostman, S. J., Fernandez, C., Burnett, J. C. & Huryn, D. M. Do Zebrafish Obey Lipinski Rules? ACS Med. Chem. Lett. 10, 1002\u20131006 (2019).","journal-title":"ACS Med. Chem. Lett."},{"key":"52173_CR43","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong, S. et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712\u2013716 (2016).","journal-title":"Science"},{"key":"52173_CR44","doi-asserted-by":"publisher","first-page":"e12914","DOI":"10.1111\/bpa.12914","volume":"31","author":"N Briel","year":"2021","unstructured":"Briel, N., Pratsch, K., Roeber, S., Arzberger, T. & Herms, J. Contribution of the astrocytic tau pathology to synapse loss in progressive supranuclear palsy and corticobasal degeneration. Brain Pathol. 31, e12914 (2021).","journal-title":"Brain Pathol."},{"key":"52173_CR45","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/jnen\/60.5.403","volume":"60","author":"EH Bigio","year":"2001","unstructured":"Bigio, E. H. et al. Cortical Synapse Loss in progressive Supranuclear palsy. J. Neuropathol. Exp. Neurol. 60, 403\u2013410 (2001).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"52173_CR46","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1046\/j.1471-4159.1997.68051836.x","volume":"68","author":"KA Hartnett","year":"1997","unstructured":"Hartnett, K. A. et al. NMDA receptor-mediated neurotoxicity: a paradoxical requirement for extracellular Mg2+ in Na+\/Ca2+-free solutions in rat cortical neurons in vitro. J. Neurochem. 68, 1836\u20131845 (1997).","journal-title":"J. Neurochem."},{"key":"52173_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01819-z","volume":"17","author":"N Goshi","year":"2020","unstructured":"Goshi, N., Morgan, R. K., Lein, P. J. & Seker, E. A primary neural cell culture model to study neuron, astrocyte, and microglia interactions in neuroinflammation. J. Neuroinflammation 17, 155 (2020).","journal-title":"J. Neuroinflammation"},{"key":"52173_CR48","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067\u20131073 (2010).","journal-title":"Nature"},{"key":"52173_CR49","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1128\/MCB.01365-08","volume":"29","author":"B Huang","year":"2009","unstructured":"Huang, B., Yang, X. D., Zhou, M. M., Ozato, K. & Chen, L. F. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol. Cell Biol. 29, 1375\u20131387 (2009).","journal-title":"Mol. Cell Biol."},{"key":"52173_CR50","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1002\/dvdy.21576","volume":"237","author":"R Toyama","year":"2008","unstructured":"Toyama, R., Rebbert, M. L., Dey, A., Ozato, K. & Dawid, I. B. Brd4 associates with mitotic chromosomes throughout early zebrafish embryogenesis. Dev. Dyn. 237, 1636\u20131644 (2008).","journal-title":"Dev. Dyn."},{"key":"52173_CR51","doi-asserted-by":"publisher","first-page":"eaay5947","DOI":"10.1126\/science.aay5947","volume":"367","author":"E Sj\u00f6stedt","year":"2020","unstructured":"Sj\u00f6stedt, E. et al. An atlas of the protein-coding genes in the human, pig, and mouse brain. Science 367, eaay5947 (2020).","journal-title":"Science"},{"key":"52173_CR52","doi-asserted-by":"publisher","first-page":"e100293","DOI":"10.15252\/embj.2018100293","volume":"38","author":"A Dey","year":"2019","unstructured":"Dey, A. et al. BRD4 directs hematopoietic stem cell development and modulates macrophage inflammatory responses. EMBO J. 38, e100293 (2019).","journal-title":"EMBO J."},{"key":"52173_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-023-01534-9","volume":"11","author":"CV Tauber","year":"2023","unstructured":"Tauber, C. V. et al. Different MAPT haplotypes influence expression of total MAPT in postmortem brain tissue. Acta Neuropathologica Commun. 11, 40 (2023).","journal-title":"Acta Neuropathologica Commun."},{"key":"52173_CR54","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","volume":"53","author":"Y Yoshiyama","year":"2007","unstructured":"Yoshiyama, Y. et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337\u2013351 (2007).","journal-title":"Neuron"},{"key":"52173_CR55","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.neuron.2018.10.031","volume":"100","author":"A Litvinchuk","year":"2018","unstructured":"Litvinchuk, A. et al. Complement C3aR Inactivation Attenuates Tau Pathology and Reverses an Immune Network Deregulated in Tauopathy Models and Alzheimer\u2019s Disease. Neuron 100, 1337\u20131353 e1335 (2018).","journal-title":"Neuron"},{"key":"52173_CR56","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00401-015-1458-4","volume":"130","author":"M Iba","year":"2015","unstructured":"Iba, M. et al. Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC\u2019s afferent and efferent connections. Acta Neuropathol. 130, 349\u2013362 (2015).","journal-title":"Acta Neuropathol."},{"key":"52173_CR57","doi-asserted-by":"crossref","unstructured":"Shi, Q. et al. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP\/PS1 mice. Sci. Transl. Med. 9, eaaf6295 (2017).","DOI":"10.1126\/scitranslmed.aaf6295"},{"key":"52173_CR58","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.celrep.2019.07.060","volume":"28","author":"T Wu","year":"2019","unstructured":"Wu, T. et al. Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy. Cell Rep. 28, 2111\u20132123.e2116 (2019).","journal-title":"Cell Rep."},{"key":"52173_CR59","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.neuron.2018.10.014","volume":"100","author":"B Dejanovic","year":"2018","unstructured":"Dejanovic, B. et al. Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies. Neuron 100, 1322\u20131336 e1327 (2018).","journal-title":"Neuron"},{"key":"52173_CR60","doi-asserted-by":"publisher","first-page":"eadf0141","DOI":"10.1126\/scitranslmed.adf0141","volume":"15","author":"J Zhou","year":"2023","unstructured":"Zhou, J. et al. The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration. Sci. Transl. Med. 15, eadf0141 (2023).","journal-title":"Sci. Transl. Med."},{"key":"52173_CR61","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s12265-017-9755-z","volume":"10","author":"S Wasiak","year":"2017","unstructured":"Wasiak, S. et al. Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208). J. Cardiovasc. Transl. Res. 10, 337\u2013347 (2017).","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"52173_CR62","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1111\/jcmm.14196","volume":"23","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. BRD4 inhibition attenuates inflammatory response in microglia and facilitates recovery after spinal cord injury in rats. J. Cell Mol. Med. 23, 3214\u20133223 (2019).","journal-title":"J. Cell Mol. Med."},{"key":"52173_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46516-x","volume":"9","author":"HR Gibbons","year":"2019","unstructured":"Gibbons, H. R. et al. Bromodomain inhibitor JQ1 reversibly blocks IFN-\u03b3 production. Sci. Rep. 9, 10280 (2019).","journal-title":"Sci. Rep."},{"key":"52173_CR64","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13578-018-0258-7","volume":"8","author":"H Wang","year":"2018","unstructured":"Wang, H. et al. (+)-JQ1 attenuated LPS-induced microglial inflammation via MAPK\/NFkappaB signaling. Cell Biosci. 8, 60 (2018).","journal-title":"Cell Biosci."},{"key":"52173_CR65","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.dci.2014.01.010","volume":"46","author":"S Zhang","year":"2014","unstructured":"Zhang, S. & Cui, P. Complement system in zebrafish. Dev. Comp. Immunol. 46, 3\u201310 (2014).","journal-title":"Dev. Comp. Immunol."},{"key":"52173_CR66","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/glia.23717","volume":"68","author":"J Mazzolini","year":"2020","unstructured":"Mazzolini, J. et al. Gene expression profiling reveals a conserved microglia signature in larval zebrafish. Glia 68, 298\u2013315 (2020).","journal-title":"Glia"},{"key":"52173_CR67","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.cell.2008.04.037","volume":"133","author":"F Peri","year":"2008","unstructured":"Peri, F. & Nusslein-Volhard, C. Live imaging of neuronal degradation by microglia reveals a role for v0-ATPase a1 in phagosomal fusion in vivo. Cell 133, 916\u2013927 (2008).","journal-title":"Cell"},{"key":"52173_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42626-3","volume":"14","author":"Y Min","year":"2023","unstructured":"Min, Y. et al. Cross species systems biology discovers glial DDR2, STOM, and KANK2 as therapeutic targets in progressive supranuclear palsy. Nat. Commun. 14, 6801 (2023).","journal-title":"Nat. Commun."},{"key":"52173_CR69","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41573-019-0030-7","volume":"18","author":"AG Cochran","year":"2019","unstructured":"Cochran, A. G., Conery, A. R. & Sims, R. J. Bromodomains: a new target class for drug development. Nat. Rev. Drug Discov. 18, 609\u2013628 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"52173_CR70","doi-asserted-by":"publisher","first-page":"621093","DOI":"10.3389\/fphar.2020.621093","volume":"11","author":"Y Sun","year":"2020","unstructured":"Sun, Y. et al. Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials. Front Pharm. 11, 621093 (2020).","journal-title":"Front Pharm."},{"key":"52173_CR71","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2174\/1567205013666160427101832","volume":"13","author":"M Magistri","year":"2016","unstructured":"Magistri, M. et al. The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer\u2019s Disease. Curr. Alzheimer Res. 13, 985\u2013995 (2016).","journal-title":"Curr. Alzheimer Res."},{"key":"52173_CR72","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/ana.25911","volume":"88","author":"M Malpetti","year":"2020","unstructured":"Malpetti, M. et al. Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy. Ann. Neurol. 88, 1194\u20131204 (2020).","journal-title":"Ann. Neurol."},{"key":"52173_CR73","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/brain\/awab282","volume":"145","author":"N Holland","year":"2022","unstructured":"Holland, N. et al. Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study. Brain 145, 340\u2013348 (2022).","journal-title":"Brain"},{"key":"52173_CR74","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/hmg\/ddz264","volume":"29","author":"AJ Kedaigle","year":"2019","unstructured":"Kedaigle, A. J. et al. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6\/2 Huntington\u2019s disease mice. Hum. Mol. Genet. 29, 202\u2013215 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"52173_CR75","doi-asserted-by":"publisher","first-page":"101794","DOI":"10.1016\/j.jbc.2022.101794","volume":"298","author":"S Zhang","year":"2022","unstructured":"Zhang, S. et al. Degradation and inhibition of epigenetic regulatory protein BRD4 exacerbate Alzheimer\u2019s disease-related neuropathology in cell models. J. Biol. Chem. 298, 101794 (2022).","journal-title":"J. Biol. Chem."},{"key":"52173_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0750-2","volume":"7","author":"E Rossaert","year":"2019","unstructured":"Rossaert, E. et al. Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model. Acta Neuropathologica Commun. 7, 107 (2019).","journal-title":"Acta Neuropathologica Commun."},{"key":"52173_CR77","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.2174\/1570159X16666180110130253","volume":"16","author":"A Merelli","year":"2018","unstructured":"Merelli, A. et al. Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities. Curr. Neuropharmacol. 16, 1484\u20131498 (2018).","journal-title":"Curr. Neuropharmacol."},{"key":"52173_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05325-y","volume":"9","author":"A Weber","year":"2018","unstructured":"Weber, A. et al. Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1. Nat. Commun. 9, 2929 (2018).","journal-title":"Nat. Commun."},{"key":"52173_CR79","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1073\/pnas.0704963105","volume":"105","author":"K Asakawa","year":"2008","unstructured":"Asakawa, K. et al. Genetic dissection of neural circuits by Tol2 transposon-mediated Gal4 gene and enhancer trapping in zebrafish. Proc. Natl Acad. Sci. USA 105, 1255\u20131260 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"52173_CR80","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.nbd.2016.07.020","volume":"95","author":"AA Dukes","year":"2016","unstructured":"Dukes, A. A. et al. Live imaging of mitochondrial dynamics in CNS dopaminergic neurons in vivo demonstrates early reversal of mitochondrial transport following MPP(+) exposure. Neurobiol. Dis. 95, 238\u2013249 (2016).","journal-title":"Neurobiol. Dis."},{"key":"52173_CR81","doi-asserted-by":"publisher","first-page":"e51845","DOI":"10.7554\/eLife.51845","volume":"9","author":"W Xie","year":"2020","unstructured":"Xie, W. et al. Chemoptogenetic ablation of neuronal mitochondria in vivo with spatiotemporal precision and controllable severity. eLife 9, e51845 (2020).","journal-title":"eLife"},{"key":"52173_CR82","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1523\/JNEUROSCI.2124-20.2021","volume":"41","author":"VA Ilin","year":"2021","unstructured":"Ilin, V. A., Bai, Q., Watson, A. M., Volgushev, M. & Burton, E. A. Mechanism of pacemaker activity in zebrafish DC2\/4 dopaminergic neurons. J. Neurosci. 41, 4141\u20134157 (2021).","journal-title":"J. Neurosci."},{"key":"52173_CR83","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1182\/blood-2010-10-314120","volume":"117","author":"F Ellett","year":"2011","unstructured":"Ellett, F., Pase, L., Hayman, J. W., Andrianopoulos, A. & Lieschke, G. J. mpeg1 promoter transgenes direct macrophage-lineage expression in zebrafish. Blood 117, e49\u2013e56 (2011).","journal-title":"Blood"},{"key":"52173_CR84","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675 (2012).","journal-title":"Nat. Methods"},{"key":"52173_CR85","doi-asserted-by":"publisher","first-page":"24114","DOI":"10.1074\/jbc.M113.545426","volume":"289","author":"Q Bai","year":"2014","unstructured":"Bai, Q., Parris, R. S. & Burton, E. A. Different mechanisms regulate expression of zebrafish myelin protein zero (P0) in myelinating oligodendrocytes and its induction following axonal injury. J. Biol. Chem. 289, 24114\u201324128 (2014).","journal-title":"J. Biol. Chem."},{"key":"52173_CR86","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00401-022-02479-4","volume":"144","author":"SF Roemer","year":"2022","unstructured":"Roemer, S. F. et al. Rainwater Charitable Foundation criteria for the neuropathologic diagnosis of progressive supranuclear palsy. Acta Neuropathol. 144, 603\u2013614 (2022).","journal-title":"Acta Neuropathol."},{"key":"52173_CR87","doi-asserted-by":"publisher","first-page":"134490","DOI":"10.1016\/j.scitotenv.2019.134490","volume":"709","author":"M Christou","year":"2020","unstructured":"Christou, M., Kavaliauskis, A., Ropstad, E. & Fraser, T. W. K. DMSO effects larval zebrafish (Danio rerio) behavior, with additive and interaction effects when combined with positive controls. Sci. Total Environ. 709, 134490 (2020).","journal-title":"Sci. Total Environ."},{"key":"52173_CR88","doi-asserted-by":"crossref","unstructured":"Hoyberghs, J. et al. DMSO Concentrations up to 1% are Safe to be Used in the Zebrafish Embryo Developmental Toxicity Assay. Front. Toxicol. 3, 804033 (2021).","DOI":"10.3389\/ftox.2021.804033"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52173-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52173-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52173-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T22:57:17Z","timestamp":1726786637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52173-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52173"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-52173-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]},"assertion":[{"value":"11 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8195"}}